Cargando…

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)

Talimogene laherparepvec (T‐VEC) is a genetically modified herpes simplex virus‐1‐based oncolytic immunotherapy and has been approved for the local treatment of unresectable (stage IIIB/C and IVM1a) cutaneous melanoma. During T‐VEC treatment, tumor response is often evaluated using [18F]2‐fluoro‐2‐d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulder, Evalyn E. A. P., Stahlie, Emma H. A., Verver, Daniëlle, Lemstra, Clara, Been, Lukas B., Mooyaart, Antien L., Brabander, Tessa, Vegt, Erik, Verburg, Frederik A., van der Veldt, Astrid A. M., Verhoef, Cornelis, van Akkooi, Alexander C. J., Grünhagen, Dirk J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Melanoma, Sarcoma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596632/ https://www.ncbi.nlm.nih.gov/pubmed/34235758 http://dx.doi.org/10.1002/jso.26607

Ejemplares similares

Outcome after treatment for sebaceous carcinoma: A multicenter study
por: In 't Veld, Eva Huis, et al.
Publicado: (2022)

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
por: Andtbacka, Robert H. I., et al.
Publicado: (2016)

Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma
por: Mulder, Evalyn E.A.P., et al.
Publicado: (2022)

Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma
por: Huis in ’t Veld, Eva A., et al.
Publicado: (2023)

External validation and adaptation of a dynamic prediction model for patients with high‐grade extremity soft tissue sarcoma
por: Rueten‐Budde, Anja J., et al.
Publicado: (2020)

Obesity is not associated with disease‐free interval, melanoma‐specific survival, or overall survival in patients with clinical stage IB‐II melanoma after SLNB
por: Deckers, Eric A., et al.
Publicado: (2021)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Factors associated with disease‐free and abdominal recurrence‐free survival in abdominopelvic and retroperitoneal sarcomas
por: Bredbeck, Brooke C., et al.
Publicado: (2022)

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy
por: Zhang, Tiantian, et al.
Publicado: (2023)

Clinicopathologic models predicting non‐sentinel lymph node metastasis in cutaneous melanoma patients: Are they useful for patients with a single positive sentinel node?
por: Rentroia‐Pacheco, Barbara, et al.
Publicado: (2021)

Potential Cost-Effectiveness of US-Guided FNAC in Melanoma Patients as a Primary Procedure and in Follow-Up
por: van Akkooi, Alexander C. J., et al.
Publicado: (2009)

Isolated Tumor Cells and Long-Term Prognosis of Patients with Melanoma
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Cutaneous Melanoma and Sentinel Lymph Node Biopsy
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
por: Rehman, Hasan, et al.
Publicado: (2016)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
por: Tijtgat, Jens, et al.
Publicado: (2021)

Risk Factors for Positive Deep Pelvic Nodal Involvement in Patients with Palpable Groin Melanoma Metastases: Can the Extent of Surgery be Safely Minimized?: A Retrospective, Multicenter Cohort Study
por: Oude Ophuis, C. M. C., et al.
Publicado: (2015)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
por: Ressler, Julia Maria, et al.
Publicado: (2021)

Therapeutic Surgical Management of Palpable Melanoma Groin Metastases: Superficial or Combined Superficial and Deep Groin Lymph Node Dissection
por: van der Ploeg, A. P. T., et al.
Publicado: (2011)

Management of Soft Tissue Sarcomas in Extremities: Variation in Treatment Recommendations and Surveillance According to Specialty and Continent
por: Acem, Ibtissam, et al.
Publicado: (2021)

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Publicado: (2021)

Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
por: Lalu, Manoj, et al.
Publicado: (2019)

Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site
por: Prens, Sebastiaan P., et al.
Publicado: (2011)

Talimogene laherparepvec (T‐VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report
por: Ressler, J., et al.
Publicado: (2019)

A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors
por: Hecht, J Randolph, et al.
Publicado: (2015)

A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site
por: Gos, Aleksandra, et al.
Publicado: (2014)

Risk factors for local atypical fibroxanthoma recurrence and progression to pleomorphic dermal sarcoma: A meta‐analysis of individualized participant data
por: Ørholt, Mathias, et al.
Publicado: (2022)

Synovial sarcomas: A single surgeon experience of 130 cases
por: Andreani, Lorenzo, et al.
Publicado: (2022)

Intralesional margin after excision of a high‐grade osteosarcoma: Is it a catastrophe?
por: Tsagkozis, Panagiotis, et al.
Publicado: (2022)

Subcostal lymph nodes: An unusual sentinel lymph node basin in cutaneous melanoma
por: Marsh, Katherine M., et al.
Publicado: (2022)

Multimarker Reverse Transcriptase-Polymerase Chain Reaction Assay in Lymphatic Drainage and Sentinel Node Tumor Burden
por: Rutkowski, Piotr, et al.
Publicado: (2010)

Talimogene laherparepvec: First in class oncolytic virotherapy
por: Conry, Robert M., et al.
Publicado: (2018)

Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
por: Kleemann, Johannes, et al.
Publicado: (2021)

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma
por: Ahamadi, Malidi, et al.
Publicado: (2023)

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
por: McClure, Erin M., et al.
Publicado: (2022)

20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters
por: Deroose, Jan P., et al.
Publicado: (2011)

Morbidity After Inguinal Lymph Node Dissections: It Is Time for a Change
por: Faut, Marloes, et al.
Publicado: (2016)

Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients
por: Faut, Marloes, et al.
Publicado: (2016)

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
por: Blake, Zoë, et al.
Publicado: (2018)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
por: Andtbacka, Robert H.I., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ljiqhsit718h1bg1o1sbanrp7t